51 results about "Glycophorin" patented technology

Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells.In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the plasmodium vivax Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide.The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus.The resulting fusion peptide being exemplified asNH2-CD4-GBP130-COOH1-371 201-774Also disclosed are the methods of manufacture and means to use the novel hybrid peptides as clinical agents to treat, prevent or test for HIV infection.

Populations of stem cells and methods for their isolation and use are provided. These stem cell populations comprise aldehyde dehydrogenase positive (ALDHbr) cells isolated from bone marrow, and ALDHbr CD105+ cells derived from any stem cell source. These populations may also comprise cells expressing such surface markers as CD34, CD38, CD41, CD45, CD105, CD133, CD135, CD117, and HLA-DR, and / or are substantially free from such cell surface markers as CD3, CD7, CD 10, CD 13, CD 14, C1319, CD33, CD35, CD56, CD 127, CD 138, and glycophorin A. The population may also comprise cells expressing CD90. The stem cell populations of the invention are isolated from a stem cell source such as bone marrow, peripheral blood, umbilical cord blood, and fetal liver. Methods of the invention comprise isolating and purifying stem cell populations from stem cell sources, and methods of using these cells to reconstitute, repair, and regenerate tissues.

The invention relates to a new class of compounds, which are 1-phenylalcoxy-2-β-phenylethyl derivatives, as P-glycoprotein (P-GP) inhibitors. These compounds are useful in drug resistance events. They have been shown able to inhibit in a dose-dependent manner Glycoprotein-P (P-gp) activity in cell lines in which the expression of said glycoprotein is very high, like Caco-2 (human colon cancer) cells and MCF7 / Adr (adriamycin-resistant human breast carcinoma) cells. The invention also relates to methods of production and the utilization of such compounds as medicaments useful in the treatment of states linked to the difficulty for some drugs to cross the blood-brain barrier (BBB) and generally within the context of the problems of drug resistance induced by chemotherapy agents.

Methods of isolating and cryopreserving progenitors from human liver are disclosed which include processing human liver tissue to provide a substantially single cell suspension comprising progenitors and non-progenitors of one or more cell lineages found in human liver; subjecting the suspension to a debulking step, which reduces substantially the number of non-progenitors in the suspension, and which provides a debulked suspension enriched in progenitors exhibiting one or more markers associated with at least one of the one or more cell lineages; and selecting from said debulked suspension those cells, which themselves, their progeny, or more mature forms thereof express one or more markers associated with at least one of the one or more cell lineages. Among these markers are CD14, CD34, CD38, CD45, and ICAM. Hepatic progenitors are characterized as being 6-15μ in diameter, diploid, glycophorin A−, CD45−, AFP+++, ALB+, ICAM+, and with subpopulations varying in expression of CD14+. CD34++, CD38++, CD117+. These progenitor subpopulations have characteristics expected for cells that are particularly useful in liver cell and gene therapies and for establishing bioartificial organs.

This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.

An antigen-dependent negative selection blood cell separation method is described. Rare circulating epithelial cells can be separated from blood by depleting erythrocytes from a blood sample. Erythrocytes are depleted by agglutination. The new method comprises the use of an agglutinating agent, such as an anti-glycophorin A or glycophorin B antibody, as glycophorin A or B are present on erythrocytes and not on the desired epithelial cells. With regular mixing, desired rare circulating epithelial cells do not become entrapped in the red cell agglutinate.

A transgenic insect cell line for production of recombinant glycoproteins possessing sulfated, complex N-glycans is provided.

The invention provides a blood platelet antibody specificity identification method and a kit thereof. The method comprises the following steps: (1) connecting different blood platelet specificity glycoprotein to different fluorescent microsphere surfaces to obtain antigen specificity fluorescent microspheres for standby use; (2) adding the antigen specificity fluorescent microspheres into a sample to be detected to perform an incubation reaction, and washing for standby use; and (3) adding a fluorescent marked anti-human IgG into step (2) to perform the incubation reaction, washing, and performing flow cytometry detection. The blood platelet antibody specificity identification method solves the problems that the blood platelet antibody detection in the prior art mainly targets at an antigen-self blood platelet antibody complex on the surface of the blood platelet and does not detect free blood platelet antibodies in plasma or serum, and the detection result of the blood platelet antibody is imprecise; and moreover, the method is simple in steps, easy in operation, short in time comsuming and higher in efficiency.

Production of non-glycosylated protein from yeast is carried out by constructing expression carrier containing N-glycoamidase and purposive protein gene from molecular biological technology, transferred into yeasts from electric transformation, expressing N- glycoamidase on yeast cell surface, excretory expressing purposive protein into culture medium, removing chain of glucoprotein excretory expressed from N- glycoamidase surface expressed and obtaining non-glycosylated protein. It has better expression protein activity and correct tertiary structure and no immunogenicity to human body.

We describe a new two-step culture method for mass production in vitro of erythroid cells from either CD34<+> (10<5 >cells / mL) or light-density (10<6 >cells / mL) cells purified from the blood of normal donors and thalassemic patients. The method includes (i) culture of the cells in the presence of dexamethasone and estradiol (10<-6 >M each) and (ii) the growth factors SCF (50 ng / mL), IL-3 (1 ng / mL), and EPO (1 U / mL). In their proliferative phase, these cultures generated about 1-2x10<7 >erythroblasts for each milliliter of blood collected from normal donors or thalassemic patients. They were composed mostly (90%) of CD45<low> / glycophorin (GPA)<neg> / CD71<low >cells at day 7, 50-60% of which became CD45<neg> / GPA+ / CD71<high >by days 15-20. However, when cells from days 7 to 12 of the proliferative phase were transferred in differentiation medium containing EPO and insulin, they progressed to mature erythroblasts (>90% benzidine<pos >and CD45<neg> / GPA<+> / CD71<medium>) in 4 days. Because of the high number of erythroid cells that are generated from modest volumes of blood, this method will prove useful in donor-specific studies of erythroid differentiation.

The invention discloses a method for building P-glycoprotein (P-gp) research models based on human small intestine 3D (three-dimensional) organoid. The method includes inoculating human small intestine crypts in matrigel at first, adding ADMEM / F12 culture media with specific growth factors into the matrigel and cultivating the human small intestine crypts to form 3D organoids; carrying out morphological observation and detecting expression of P-gp from mRNA [messenger RNA (ribonucleic acid)] and protein level; researching influence of Verapamil and Mitotane on Rh123 transportation by the aid of a co-incubation process by Rhodamine 123 (Rh123) which is used as a substrate. The method has the advantages that the P-glycoprotein research models based on human small intestine 3D organoid can be applied to P-gp-mediated medicine transport research and also can be widely applied to in-vitro high-throughput screening on P-gp inhibitors, and the method is high in efficiency and speed.

In accordance with the present invention, there have been identified extracts from a tropical plant that initiate paclitaxel-like microtubule bundling. Bioassay-directed purification yields the steroid taccalonolide A. Taccalonolide, like paclitaxel, initiates the formation of abnormal interphaes and mitotic microtubules. Cells treated with taccalonolide exhibit thick bundles of microtubules that appear to nucleate independent of the microtubule organizing center. Abnormal mitotic spindles consisting of multi-polar spindles are initiated by taccalonolide and resemble abnormal mitotic spindles found in the presence of paclitaxel. Like paclitaxel, taccalonolide causes the breakdown of the nucleus into micronuclei. Taccalonolide causes G2 / M arrest, Bc1-2 phosphorylation and initiates an apoptotic cascade that includes the activation of caspase 3. Taccalonolide is an effective inhibitor of proliferation against both SK-OV-3 and MDA-MB-435 cell with IC50 values of 2.3 μM and 2.1 μM respectively. In contrast to paclitaxel, taccalonolide is effective against the multidrug resistant SKVLB-1 cellline and thus appears to be a poor substrate for P-glycoprotein-mediated transport. Although taccalonolide is almost equipotent with paclitaxel in its effects on cellular microtubules, it is much less potent than paclitaxel in its ability to initiate the polymerization of purified tubulin and microtubule protein. Taccalonolide A is the first microtubule stabilizing agent to be discovered from a plant since identification of the mechanism of action of paclitaxel and it is the first natural product steroid identified to have these cellular effects.

Provided is a novel method of diagnosing rheumatoid arthritis. Based on the quantitative expression profile of sugar chain expression amount in the serum (whole serum, HAP or LAP), the relevancy thereof to rheumatoid arthritis is analyzed. As a result, a sugar chain and a glycoprotein showing a change depending on the onset of rheumatoid arthritis are found out and thus a serum sugar chain and a glycoprotein usable as a novel biomarker are provided.

The present invention provides a monoclonal antibody that recognizes the V3 loop of the envelope glycoprotein gp120 of AIDS virus, which is any one selected from the following antibodies:(a) an antibody having the amino acid sequence shown in SEQ ID NO: 1 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 2 as the amino acid sequence of a L chain variable region (VL); and(b) an antibody having the amino acid sequence shown in SEQ ID NO: 3 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 4 as the amino acid sequence of a L chain variable region (VL).

Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and / or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and / or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.

The invention provides a medicine for treating pulmonary tuberculosis. The medicine is mixture of glucoprotein or polysaccharide and protein or is polypeptide or protein. The medicine provided by the invention has a favorable curative effect on pulmonary tuberculosis, is capable of obviously improving the sputum negative conversion rate, the focal absorption rate and the cavity closing rate, reducing the number of colonies of the lung and spleen, increasing the quantity of T lymphocytes CD4<+>T, increasing the thymus index and increasing the IFN-gamma content after being used for treating pulmonary tuberculosis for three months, is safe, efficient and free of side effect, and has obvious effects on preventing and treating pulmonary tuberculosis.

The invention relates to a biomark detection method of Alzheimer's disease, which comprises the following steps: (1) collecting and processing a serum sample; (2) performing fluorescence marking on an oligosaccharide in the serum sample with a fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) technology through a DNA-based sequencer; (3) measuring content of the oligosaccharide subjected to fluorescence marking in the sample by ionophortic separation and obtaining an oligosaccharide fingerprint spectrum; (4) analyzing the oligosaccharide fingerprint spectrum. The difficult detection of the Alzheimer's disease is solved, the Alzheimer's disease can be quantitatively detected and a pathogenetic degree can be quantitatively evaluated.

The present invention pertains to the field of recombinant protein production. Novel peptides derived from the extracellular region of a glycophorin protein are provided which enhance the expression rate of proteins or peptides of interest when expressed as fusion protein together with said novel peptides.

Amooranin (AMR) has been found to cause tumor cell death through G2 / M cell cycle arrest, caspase activation, and apoptosis. Furthermore, it has been demonstrated that AMR is a substrate for P-glycoprotein. Based on these activities, AMR compounds, including AMR analogs, can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.

A Chaenomeles lagenaria extract having a lectin specific for glycophorin A and method for extracting the same are proposed. The extract is prepared by homogenizing seeds of Chaenomeles lagenaria with a homogenizing agent into a mixture, and the mixture is further processed to produce the extract both effective in inhibiting tumor growth and applicable to a blood typing test.

The present invention provides a method by which lung squamous cell carcinoma can be detected in a simple and prompt manner with high detection performance; and the like. The method according to the present invention detects lung squamous cell carcinoma by an assessment including the steps of: (1) performing measurement of the desmoglein 3 content in a blood sample collected from a subject; and (2) comparing the desmoglein 3 content determined by the measurement with the desmoglein 3 content in a blood sample collected from a healthy individual so as to estimate the presence of lung squamous cell carcinoma in the subject when the desmoglein 3 content is higher in the blood sample collected from the subject.

The invention discloses SPG-(Streptococcal Protein G) antibody polymer and a preparation method as well as application thereof. The SPG-antibody polymer is formed by coupling anti-glycophorin A monoclonal antibody, an SPG antibody and a target antigen antibody. One end of the polymer is coupled with red blood cells through the anti-glycophorin A monoclonal antibody, and the other end of the polymer is coupled with a target antigen through antibodies of a surface antigen of a target cell and other antigens; then standing is performed to detect the target antigen through red blood cell precipitation, or mature nucleated cells and red cells in blood are removed through density gradient centrifugation; and all stem cells / progenitor cells are reserved. In the invention, a combined method of negative selection and density gradient centrifugation is adopted for separating and extracting the stem cells and the progenitor cells, and markers are not available on the surfaces of the collected progenitor / stem cells, so that the antibody polymer has the advantages of high cell activity, simple and practical method, industrial production and easiness in popularization, can be widely applied to research and treatment of laboratory and clinical cell damage diseases and has broad prospect.